Videos of Professor Chris Nutting
Professor Christopher Nutting, leading cancer specialist, has joined the campaign for the UK NHS-administered HPV vaccine to be given to boys and well as girls. All girls aged 12 to 13 are offered HPV (human papilloma virus) vaccination as part of the NHS childhood vaccination programme to protect against cervical cancer. The programme was introduced in 2008 and it is estimated that about 400 lives will be saved every year in the UK as a result of vaccinating girls with Gardasil, which provides protection for at least 20 years. HPV is easily spread by sexual activity and in most cases the virus doesn’t do any harm because the body’s immune system successfully fights the infection. However in almost all cervical cancer cases, there is a history of infection with high-risk types of HPV. Nearly 3,000 women are diagnosed with cervical cancer every year in the UK. Professor Christopher Nutting, head of the Head and Neck Cancer unit at the Royal Marsden Hospital, believes the vaccination programme should be extended to boys of the same age because of the links between HPV and other cancers including the mouth and throat. He is one of hundreds of experts in 36 leading patient and professional organisations who have joined a campaign HPV Action that is lobbying the government and campaigning for the vaccine programme to be offered on a ‘gender-neutral’ basis so it offers wider protection. Professor Nutting said: “HPV can cause cancers in the back of the throat, most commonly in the base of the tongue and tonsils, in an area known as the oropharynx. Cancer caused by HPV often takes years to develop after initially getting an HPV infection. There may be other factors, such as smoking, which interacts with HPV to cause the oropharynx cancer and more research is needed in this area. “However there is a clear case that HPV vaccination can significantly reduce the risk of developing disease and vaccinating both sexes provides the highest level of protection and will produce better outcomes for all and reduce health inequality.” Professor Nutting spoke out at the start of European Immunization Week which began on Monday April 20th 2015. The NHS argues that the high take-up rate of the vaccination among girls – currently exceeding 80% - means that boys will automatically safeguarded against HPV infection through ‘herd protection.’ But Professor Nutting said: “The current cost-effectiveness analysis does not include the protective effect of HPV vaccination against head, neck, anal and penile cancers. Why doesn’t the UK follow the example of the US, Canada, Austria and Australia and recommend vaccination for boys as well as girls?” The HPV vaccine is delivered largely through secondary schools, and consists of two injections into the upper arm spaced at least six, and not more than 24, months apart while girls who began vaccination before September last year receive three injections. If you wish to arrange a consultation with Professor Christopher Nutting, you can find information on his website www.chrisnutting-oncology.com
A short interview and discussion with Professor Christopher Nutting, leading London oncologist and specialist in head and neck cancer diagnosis and treatment. This video is about 5 mins long and covers the following topics: - Coping with Cancer: - The Diagnosis - The Treatment - What You Can Do To Help - Recovery and the future - Reducing Risk Professor Nutting offers consultations from his London offices and is affiliated to and works from hospitals in the London area. Chris Nutting can put patients at ease and advise on many different types of head and neck cancer, whether that be thyroid cancer, mouth cancer amongst others. With a friendly expert team during all therapies and consultations, treatments have a high success rate, to read some real patient journeys, visit the site in the link below. For further information and to read Professor Nutting's blog, please visit http://www.chrisnutting-oncology.co.uk/
Honorary Oracle Trustee and one of the world's leading authorities on head and neck radiotherapy treatment, Professor Chris Nutting explains how Oracle's early funded work in 2004 resulted in a UK-wide trial on IMRT, a revised form of radiotherapy, that reduced the common side-effects of dry mouth and swallowing.